Clinical Trials Logo

Clinical Trial Summary

This is a phase II, multicenter, randomized open-label and comparative study designed to evaluate whether local consolidative radiotherapy plus standard of care improves overall survival as compared to standard of care in patients with limited metastatic urothelial bladder cancer and without progression following the initial phase of first-line systemic therapy. Each patient will be followed during 4 years from the date of randomization.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04428554
Study type Interventional
Source Institut Claudius Regaud
Contact Jonathan KHALIFA
Phone 05 31 15 54 01
Email khalifa.jonathan@iuct-oncopole.fr
Status Recruiting
Phase Phase 2
Start date June 30, 2020
Completion date July 2028

See also
  Status Clinical Trial Phase
Completed NCT02527434 - Study of Tremelimumab in Patients With Advanced Solid Tumors Phase 2
Recruiting NCT06335667 - mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer N/A
Terminated NCT04197986 - Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations Phase 3
Recruiting NCT05080998 - CxBladder Surveillance of Intermediate and High-Risk Bladder Cancer Patients
Suspended NCT04779151 - Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab Phase 2